文献速递淋巴瘤

新型Ⅰ类和Ⅱb类选择性组蛋白去乙酰化酶抑制剂甲磺酸普依司他对弥漫大B细胞淋巴瘤的体外药效学研究及其机制

[In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

该研究用MTT法、流式细胞术和Western blot检测新型Ⅰ类和Ⅱb类选择性HDAC抑制剂甲磺酸普依司他对弥漫大B细胞淋巴瘤细胞株SUDHL-4和SUDHL-6的体外作用。结果显示PM明显抑制两株细胞增殖、上调H3、H4和α-tubulin乙酰化水平、诱导G(0)/G(1)期阻滞和凋亡,并下调MYC、IKZF1、IKZF3表达。结论认为PM在体外对弥漫大B细胞淋巴瘤包括双打击淋巴瘤具有高效生物活性。

要点

  • PM明显抑制淋巴瘤SUDHL-4和SUDHL-6细胞增殖,并上调H3、H4和α-tubulin乙酰化水平。
  • PM诱导SUDHL-4和SUDHL-6细胞G(0)/G(1)期阻滞,下调Cdk2、Cdk4、Cdk6、Cyclin D1、Cyclin E并上调p21。
  • PM诱导两株细胞凋亡,激活Caspase3并影响抗凋亡蛋白Bcl-2,同时下调MYC、IKZF1、IKZF3。

核心结论

  • PM在体外对弥漫大B细胞淋巴瘤包括双打击淋巴瘤具有高效的生物活性,为PM应用于临床治疗提供了有价值的实验依据。

研究设计与样本

  • 体外药效学研究,采用MTT法检测PM对细胞增殖的影响,流式细胞术检测细胞周期与凋亡,Western blot检测HDAC底物乙酰化水平、细胞周期蛋白、凋亡相关蛋白和癌基因蛋白表达。
  • 研究对象为淋巴瘤细胞株SUDHL-4和SUDHL-6。

主要发现

  • PM对淋巴瘤细胞株SUDHL-4和SUDHL-6的增殖具有明显抑制作用,并上调HDAC底物H3、H4和α-tubulin乙酰化水平。
  • 细胞周期实验中PM诱导SUDHL-4、SUDHL-6细胞G(0)/G(1)期阻滞,Western blot显示PM显著下调Cdk2、Cdk4、Cdk6及Cyclin D1、Cyclin E表达,上调CDK抑制蛋白p21表达。
  • 细胞凋亡实验中PM诱导SUDHL-4和SUDHL-6细胞凋亡,Western blot显示PM通过激活Caspase3激酶和影响抗凋亡蛋白Bcl-2促进细胞内源性凋亡。
  • PM下调癌基因标志蛋白MYC、IKZF1、IKZF3的表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the in vitro inhibitory activity of a novel class Ⅰ and Ⅱb selective histone deacetylase (HDAC) inhibitor, purinostat mesylate (PM) , in diffuse large B-cell lymphoma and its mechanism. Methods: The 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide method was used to detect the effect of PM on cell proliferation. The effects of PM on cell cycle and apoptosis were detected by flow cytometry. The acetylation levels of HDAC substrate, cell cycle protein, apoptosis-related protein, and oncogene protein expression were detected by Western blot. Results: PM significantly inhibited the proliferation of lymphoma SUDHL-4 and SUDHL-6 cells and increased the acetylation levels of HDAC substrates H3, H4, and α-tubulin. In cell cycle experiments, PM induced G(0)/G(1) phase arrest in SUDHL-4 and SUDHL-6 cells. Western blot experiment showed that PM could significantly downregulate the expression of cyclin-dependent kinases Cdk2, Cdk4, Cdk6, cyclin D1, and cyclin E and upregulate the expression of CDK inhibitor protein p21. In the apoptosis experiment, PM could induce the apoptosis of SUDHL-4 and SUDHL-6 cells. Western blot experiment demonstrated that PM promoted endogenous apoptosis by activating caspase-3 kinase and affecting antiapoptotic protein Bcl-2. In addition, PM could downregulate the expression of oncogene marker proteins MYC, IKZF1, and IKZF3. Conclusion: PM has an efficient biological activity in vitro for diffuse large B-cell lymphoma, including double-hit lymphoma, and provides valuable experimental evidence for PM in clinical treatment. 目的: 探究新型Ⅰ类和Ⅱb类选择性组蛋白去乙酰化酶(HDAC)抑制剂甲磺酸普依司他(PM)对弥漫大B细胞淋巴瘤的体外抑制活性及作用机制。 方法: MTT法检测PM对细胞增殖的影响,流式细胞术检测PM对细胞周期、细胞凋亡的影响,Western blot法检测HDAC底物乙酰化水平、细胞周期蛋白、凋亡相关蛋白和癌基因蛋白的表达。 结果: PM对淋巴瘤细胞株SUDHL-4和SUDHL-6的增殖具有明显抑制作用,能够上调HDAC底物H3、H4和α-tubulin乙酰化水平。在细胞周期实验中,PM可诱导SUDHL-4、SUDHL-6细胞G(0)/G(1)期阻滞,Western blot显示PM能显著下调细胞周期蛋白依赖性激酶Cdk2、Cdk4、Cdk6及细胞周期蛋白Cyclin D1、Cyclin E的表达,上调CDK抑制蛋白p21的表达。在细胞凋亡实验中,PM可诱导SUDHL-4和SUDHL-6细胞凋亡,Western blot显示PM通过激活Caspase3激酶和影响抗凋亡蛋白Bcl-2促进细胞内源性凋亡。此外,PM也能够下调癌基因标志蛋白MYC、IKZF1、IKZF3的表达。 结论: PM在体外对弥漫大B细胞淋巴瘤包括双打击淋巴瘤具有高效的生物活性,为PM应用于临床治疗提供了有价值的实验依据。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhao AL, Li H, et al. [In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709169. doi:10.3760/cma.j.issn.0253-2727.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。